active
ACTIVE SINCE: 2020

AMR Action Fund

The AMR Action Fund is the world’s largest public-private partnership investing in the development of new antimicrobial drugs.
SGDS CONTRIBUTING TO:
SHOW SUB-TARGETS + HIDE SUB-TARGETS -
Private Foundation or Development Organization 1
Pharma Company Foundation 2
Financial Institutions 1
Intergovernmental Organizations and Multilaterals 1
Objectives

The AMR Action Fund aims to enable breakthroughs in antimicrobials, helping to launch two to four new antimicrobials within the next decade and create a sustainable ecosystem of investment and innovation to take on one of the biggest global health challenges of our generation.

The world is losing one of its most powerful tools in healthcare: antibiotics and other antimicrobial drugs.

Antimicrobials are a cornerstone of modern medicine that have saved many millions of lives and alleviated untold suffering. But the rise of antimicrobial resistance (AMR) imperils patients and jeopardizes clinicians’ ability to safely provide a wide range of care, from performing surgery and organ transplantations to treating cancer and delivering babies.

Antimicrobial-resistant bacteria now kill nearly 1.3 million people a year. This is a rapidly evolving threat that imperils human health and could cost the global economy tens of trillions of dollars. As resistant pathogens emerge, the need for new antimicrobial therapeutics becomes more urgent every year.

A paucity of investment and innovation

Because new antimicrobials are used sparingly, companies struggle to recoup their investments. As a result, private investment into the field is low and several biotechs have gone bankrupt in recent years after successfully developing new antibiotics.

A catalyst for innovation

The AMR Action Fund is the world’s largest public-private partnership investing in the development of new antimicrobial therapeutics.

The concept of the AMR Action Fund was developed by the IFPMA and its member biopharmaceutical companies, in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust.

How the Fund invests

The AMR Action Fund has a clear scope to focus investments on clinical-stage companies that are pursuing both traditional small-molecule compounds and innovative modalities, such as bacteriophages and antibody treatments. The Fund’s Scientific Advisory Board (SAB) members, who are recognized around the world as leading experts across pertinent disciplines, including antibiotic development, clinical trial design, and pharmaceutical manufacturing, ensuring the highest level of diligence for potential investments.

Results and milestones

The AMR Action Fund has made a series of investment announcements, which can be consulted here.

Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Partner organizations
Private Foundation or Development Organization

Wellcome Trust

Pharma Company Foundation

Boehringer Ingelheim Foundation

Novo Nordisk Foundation

Financial Institutions

European Investment Bank (EIB)

Intergovernmental Organizations and Multilaterals

World Health Organization (WHO)

Additional resources